MINI LONG - NOVO-NORDISK B | Real-time Bid/Ask 12:37:43 25/06/2024 pm IST | ||
| 19.08 EUR / 19.09 EUR | +0.82% |
|
| Current month | +9.42% | ||
| 1 month | +7.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 18.93 | -1.15% |
| 21/24/21 | 19.15 | +1.11% |
| 20/24/20 | 18.94 | +0.69% |
| 19/24/19 | 18.81 | +0.48% |
| 18/24/18 | 18.72 | -0.16% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 12:15 am IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MD8EYN |
| ISIN | DE000MD8EYN8 |
| Date issued | 22/09/2022 |
| Strike | 278.9 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 3.17 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.2 € |
|---|---|
| Lowest since issue | 3.12 € |
| Spread | 0.05 € |
| Spread % | 0.26% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
988.4
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.48%
- Stock Market
- Certificates
- Certificat
